Evaluation of anifrolumab safety in systemic lupus erythematosus: A meta-analysis and systematic review
ObjectivesSystemic lupus erythematosus (SLE) is a chronic autoimmune disease, and type I interferon plays an important role in its pathogenesis. Anifrolumab is a new strategy for the treatment of systemic lupus erythematosus. It could antagonize the activity of all type 1 interferons by binding with...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-09-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2022.996662/full |
| _version_ | 1811266231279288320 |
|---|---|
| author | Zhihui Liu Ruijuan Cheng Yi Liu Yi Liu Yi Liu |
| author_facet | Zhihui Liu Ruijuan Cheng Yi Liu Yi Liu Yi Liu |
| author_sort | Zhihui Liu |
| collection | DOAJ |
| description | ObjectivesSystemic lupus erythematosus (SLE) is a chronic autoimmune disease, and type I interferon plays an important role in its pathogenesis. Anifrolumab is a new strategy for the treatment of systemic lupus erythematosus. It could antagonize the activity of all type 1 interferons by binding with type I interferon receptor subunit 1. The aim of our study was to evaluate the safety of anifrolumab in patients with moderate to severe SLE (excluding patients with active severe lupus nephritis or central nervous system lupus).MethodsFour databases (Embase, Cochrane, PubMed, Web of Science) were systematically searched from inception until December 2021 for randomized controlled trials (RCTs) evaluating the safety of anifrolumab versus placebo in SLE patients. Then, the incidence of adverse events in each study was aggregated using meta-analysis.ResultsA total of 1160 SLE patients from four RCTs were included in the analysis. Serious adverse events were less common in the anifrolumab group than in the placebo group (RR: 0.76, 95% CI: 0.59-0.98, p<0.03). The most common adverse events included upper respiratory tract infection (RR: 1.48, 95% CI: 1.13-1.94, P=0.004), nasopharyngitis (RR: 1.66, 95% CI: 1.25-2.20, P=0.0004), bronchitis (RR: 1.96, 95% CI: 1.32-2.92, P=0.0009), and herpes zoster (RR: 3.40, 95% CI: 1.90-6.07, P<0.0001).ConclusionAnifrolumab is considered a well-tolerated option for the treatment of SLE patients with good safety.Systematic Review Registrationhttps://inplasy.com, identifier 202230054. |
| first_indexed | 2024-04-12T20:38:20Z |
| format | Article |
| id | doaj.art-8c08a6ad92da42118ef4f4d832f87e77 |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-04-12T20:38:20Z |
| publishDate | 2022-09-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-8c08a6ad92da42118ef4f4d832f87e772022-12-22T03:17:29ZengFrontiers Media S.A.Frontiers in Immunology1664-32242022-09-011310.3389/fimmu.2022.996662996662Evaluation of anifrolumab safety in systemic lupus erythematosus: A meta-analysis and systematic reviewZhihui Liu0Ruijuan Cheng1Yi Liu2Yi Liu3Yi Liu4Department of Rheumatology and Immunology, West China Hospital, Sichuan University, Chengdu, ChinaDepartment of Rheumatology and Immunology, West China Hospital, Sichuan University, Chengdu, ChinaDepartment of Rheumatology and Immunology, West China Hospital, Sichuan University, Chengdu, ChinaRare Diseases Center, West China Hospital, Sichuan University, Chengdu, ChinaInstitute of Immunology and Inflammation, Frontiers Science Center for Disease-Related Molecular Network, West China Hospital, Sichuan University, Chengdu, ChinaObjectivesSystemic lupus erythematosus (SLE) is a chronic autoimmune disease, and type I interferon plays an important role in its pathogenesis. Anifrolumab is a new strategy for the treatment of systemic lupus erythematosus. It could antagonize the activity of all type 1 interferons by binding with type I interferon receptor subunit 1. The aim of our study was to evaluate the safety of anifrolumab in patients with moderate to severe SLE (excluding patients with active severe lupus nephritis or central nervous system lupus).MethodsFour databases (Embase, Cochrane, PubMed, Web of Science) were systematically searched from inception until December 2021 for randomized controlled trials (RCTs) evaluating the safety of anifrolumab versus placebo in SLE patients. Then, the incidence of adverse events in each study was aggregated using meta-analysis.ResultsA total of 1160 SLE patients from four RCTs were included in the analysis. Serious adverse events were less common in the anifrolumab group than in the placebo group (RR: 0.76, 95% CI: 0.59-0.98, p<0.03). The most common adverse events included upper respiratory tract infection (RR: 1.48, 95% CI: 1.13-1.94, P=0.004), nasopharyngitis (RR: 1.66, 95% CI: 1.25-2.20, P=0.0004), bronchitis (RR: 1.96, 95% CI: 1.32-2.92, P=0.0009), and herpes zoster (RR: 3.40, 95% CI: 1.90-6.07, P<0.0001).ConclusionAnifrolumab is considered a well-tolerated option for the treatment of SLE patients with good safety.Systematic Review Registrationhttps://inplasy.com, identifier 202230054.https://www.frontiersin.org/articles/10.3389/fimmu.2022.996662/fullsystemic lupus erythematosustype I interferonanifrolumabRCTsmeta-analysis |
| spellingShingle | Zhihui Liu Ruijuan Cheng Yi Liu Yi Liu Yi Liu Evaluation of anifrolumab safety in systemic lupus erythematosus: A meta-analysis and systematic review Frontiers in Immunology systemic lupus erythematosus type I interferon anifrolumab RCTs meta-analysis |
| title | Evaluation of anifrolumab safety in systemic lupus erythematosus: A meta-analysis and systematic review |
| title_full | Evaluation of anifrolumab safety in systemic lupus erythematosus: A meta-analysis and systematic review |
| title_fullStr | Evaluation of anifrolumab safety in systemic lupus erythematosus: A meta-analysis and systematic review |
| title_full_unstemmed | Evaluation of anifrolumab safety in systemic lupus erythematosus: A meta-analysis and systematic review |
| title_short | Evaluation of anifrolumab safety in systemic lupus erythematosus: A meta-analysis and systematic review |
| title_sort | evaluation of anifrolumab safety in systemic lupus erythematosus a meta analysis and systematic review |
| topic | systemic lupus erythematosus type I interferon anifrolumab RCTs meta-analysis |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2022.996662/full |
| work_keys_str_mv | AT zhihuiliu evaluationofanifrolumabsafetyinsystemiclupuserythematosusametaanalysisandsystematicreview AT ruijuancheng evaluationofanifrolumabsafetyinsystemiclupuserythematosusametaanalysisandsystematicreview AT yiliu evaluationofanifrolumabsafetyinsystemiclupuserythematosusametaanalysisandsystematicreview AT yiliu evaluationofanifrolumabsafetyinsystemiclupuserythematosusametaanalysisandsystematicreview AT yiliu evaluationofanifrolumabsafetyinsystemiclupuserythematosusametaanalysisandsystematicreview |